Hamburg says biosimilar pathway work is just beginning; Actelion shares jump on new takeover rumors;

 @FierceBiotech: High-profile banker predicts the end of the Big Biotech era. News | Follow @FierceBiotech

 @JohnCFierce: With patents expiring and innovation rare, cancer drug sales rose 3.5% in 1st 9 months in "unprecedented slowdown." Report | Follow @JohnCFierce

> At a recent summit the FDA's Margaret Hamburg had little new to add about the agency's move to create a pathway for biosimilar approvals. She did say that the agency's efforts here have just begun and would be constantly evolving. But developers looking for some guidance on the subject would have been disappointed. Report

> Renewed market buzz of a pending Actelion buyout spurred a new jump in its share price. Story

> Biotech veteran Robert Kamen has joined Third Rock as an entrepreneur in residence. Third Rock release

> The FDA has granted fast-track designation to Sanofi Pasteur's investigational Clostridium difficile vaccine candidate. Sanofi release

> ArQule's third quarter revenue numbers were bolstered by a $5 million milestone payment. Report

And Finally... Roughly a third of the population suffers from prehypertension, but doctors still don't agree on the best ways to treat the condition. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.